FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1550033196> ?p ?o ?g. }

• W1550033196 endingPage "1772" @default.
• W1550033196 startingPage "1765" @default.
• W1550033196 abstract "Abstract Forty-nine patients with primary myelodysplastic syndromes (MDS) were subclassified according to French-American-British (FAB) Cooperative Group criteria. Eight patients had acquired idiopathic sideroblastic anemia (AISA), ten had chronic myelomonocytic leukemia (CMMoL), 14 had refractory anemia (RA), nine had refractory anemia with excess blasts (RAEB), and five had refractory anemia with excess blasts in transformation (RAEB-T); three patients could not be subclassified. The actuarial median survival for patients with AISA or with RA had not been reached at 60 months of follow-up. The median survival times for patients with CMMoL, RAEB, and RAEB-T were 25, 21, and 16 months, respectively. The percentages of patients with each subtype who developed ANLL were none in AISA, 20% in CMMoL, 7% in RA, 56% in RAEB, and 40% in RAEB-T. Patients with CMMoL had a poor prognosis independent of transformation to acute nonlymphocytic leukemia (ANLL), whereas patients with RAEB and RAEB-T had a high incidence of transformation and short survival times. Clonal chromosomal abnormalities were present in bone marrow cells from 19 patients at the time of diagnosis, and two others developed an abnormal karyotype at the time of leukemic transformation. The most frequent abnormalities, including initial and evolutionary changes, were trisomy 8 (9 patients), deletion of 5q (4 patients), and deletion of 20q (4 patients). The median survival times were 32 months for patients with an abnormal karyotype, and 48 months for those with a normal karyotype (P = 0.2). Specific chromosomal abnormalities were not associated with particular histologic subtypes; however, a high percentage of patients with RAEB and RAEB-T had an abnormal clone (89% and 80%, respectively). The percentages of patients with clonal abnormalities were 13% for AISA, 20% for CMMoL, and 29% for RA. The MDS transformed to ANLL in 42% of patients with an abnormal karyotype, compared to 10% of those with an initially normal karyotype (P less than .01). Among patients with RA, RAEB, and RAEB-T, the risk of leukemic transformation was confined to those with an abnormal karyotype (P less than .01). Thus, in the present study, morphology and karyotype combined were the best indicators of outcome in patients with MDS." @default.
• W1550033196 created "2016-06-24" @default.
• W1550033196 creator A5017508359 @default.
• W1550033196 creator A5029797444 @default.
• W1550033196 creator A5040945822 @default.
• W1550033196 creator A5049320424 @default.
• W1550033196 creator A5069870635 @default.
• W1550033196 creator A5071604299 @default.
• W1550033196 date "1986-06-01" @default.
• W1550033196 modified "2023-09-28" @default.
• W1550033196 title "Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes" @default.
• W1550033196 cites W12979698 @default.
• W1550033196 cites W147310725 @default.
• W1550033196 cites W1504611261 @default.
• W1550033196 cites W1550405405 @default.
• W1550033196 cites W1557123927 @default.
• W1550033196 cites W1719540238 @default.
• W1550033196 cites W1796305773 @default.
• W1550033196 cites W1955065682 @default.
• W1550033196 cites W1977112446 @default.
• W1550033196 cites W1986830789 @default.
• W1550033196 cites W1999840271 @default.
• W1550033196 cites W2002112267 @default.
• W1550033196 cites W2003064170 @default.
• W1550033196 cites W2008604420 @default.
• W1550033196 cites W2015613619 @default.
• W1550033196 cites W2022106508 @default.
• W1550033196 cites W2026660305 @default.
• W1550033196 cites W2028924492 @default.
• W1550033196 cites W2048791837 @default.
• W1550033196 cites W2060446976 @default.
• W1550033196 cites W2067150248 @default.
• W1550033196 cites W2069932116 @default.
• W1550033196 cites W2076426515 @default.
• W1550033196 cites W2084028408 @default.
• W1550033196 cites W2087110785 @default.
• W1550033196 cites W2114617590 @default.
• W1550033196 cites W2143594378 @default.
• W1550033196 cites W2339359539 @default.
• W1550033196 cites W2400291475 @default.
• W1550033196 cites W2414653645 @default.
• W1550033196 cites W2474698873 @default.
• W1550033196 cites W3187821642 @default.
• W1550033196 cites W55409762 @default.
• W1550033196 cites W95047538 @default.
• W1550033196 cites W1983392832 @default.
• W1550033196 doi "https://doi.org/10.1182/blood.v67.6.1765.1765" @default.
• W1550033196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3708160" @default.
• W1550033196 hasPublicationYear "1986" @default.
• W1550033196 type Work @default.
• W1550033196 sameAs 1550033196 @default.
• W1550033196 citedByCount "241" @default.
• W1550033196 countsByYear W15500331962014 @default.
• W1550033196 countsByYear W15500331962017 @default.
• W1550033196 countsByYear W15500331962018 @default.
• W1550033196 countsByYear W15500331962019 @default.
• W1550033196 countsByYear W15500331962020 @default.
• W1550033196 countsByYear W15500331962021 @default.
• W1550033196 countsByYear W15500331962022 @default.
• W1550033196 crossrefType "journal-article" @default.
• W1550033196 hasAuthorship W1550033196A5017508359 @default.
• W1550033196 hasAuthorship W1550033196A5029797444 @default.
• W1550033196 hasAuthorship W1550033196A5040945822 @default.
• W1550033196 hasAuthorship W1550033196A5049320424 @default.
• W1550033196 hasAuthorship W1550033196A5069870635 @default.
• W1550033196 hasAuthorship W1550033196A5071604299 @default.
• W1550033196 hasBestOaLocation W15500331961 @default.
• W1550033196 hasConcept C104317684 @default.
• W1550033196 hasConcept C126322002 @default.
• W1550033196 hasConcept C142724271 @default.
• W1550033196 hasConcept C174475383 @default.
• W1550033196 hasConcept C2777928532 @default.
• W1550033196 hasConcept C2778248108 @default.
• W1550033196 hasConcept C2778461978 @default.
• W1550033196 hasConcept C2779188306 @default.
• W1550033196 hasConcept C2780007613 @default.
• W1550033196 hasConcept C2780365373 @default.
• W1550033196 hasConcept C2780817109 @default.
• W1550033196 hasConcept C30481170 @default.
• W1550033196 hasConcept C53226629 @default.
• W1550033196 hasConcept C54355233 @default.
• W1550033196 hasConcept C71924100 @default.
• W1550033196 hasConcept C86803240 @default.
• W1550033196 hasConcept C90924648 @default.
• W1550033196 hasConceptScore W1550033196C104317684 @default.
• W1550033196 hasConceptScore W1550033196C126322002 @default.
• W1550033196 hasConceptScore W1550033196C142724271 @default.
• W1550033196 hasConceptScore W1550033196C174475383 @default.
• W1550033196 hasConceptScore W1550033196C2777928532 @default.
• W1550033196 hasConceptScore W1550033196C2778248108 @default.
• W1550033196 hasConceptScore W1550033196C2778461978 @default.
• W1550033196 hasConceptScore W1550033196C2779188306 @default.
• W1550033196 hasConceptScore W1550033196C2780007613 @default.
• W1550033196 hasConceptScore W1550033196C2780365373 @default.
• W1550033196 hasConceptScore W1550033196C2780817109 @default.
• W1550033196 hasConceptScore W1550033196C30481170 @default.
• W1550033196 hasConceptScore W1550033196C53226629 @default.
• W1550033196 hasConceptScore W1550033196C54355233 @default.

• next